Currently, invasive blood test is a common way to perform screening for type 2 diabetes mellitus (T2DM).  The venture aims to develop and introduce a non-invasive test for early screening and monitoring of T2DM using protein biomarkers obtained from tear fluid. This alternative method can eliminate the fear, pain and wound caused by finger-pricking necessary for blood tests. Early screening and monitoring enable patients to receive timely treatment and a better prognosis, resulting in reduced potential medical expenses. The goal of the team is to turn laboratory innovations into clinical applications to foster the advancement of the healthcare industry.